USPTO Examiner BERTOGLIO VALARIE E - Art Unit 1632

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18999456TARGETING THE PVR AXIS USING CAR T CELL THERAPY AND COMBINATIONSDecember 2024June 2025Allow510NoNo
18904578ABSOLUTE PRECIPITATION OF EXOSOMES (APEX) ISOLATIONOctober 2024February 2025Allow410YesNo
18735079METHOD FOR ANALYZING CONTENT AND DISTRIBUTION OF MICROPLASTICS IN MARINE CNIDARIA ORGANISMSJune 2024January 2025Allow710NoNo
18589909UTERINE-DERIVED REGENERATIVE CELL COMPOSITIONS AND USES THEREOFFebruary 2024January 2025Allow1021YesNo
18442444Non-Human Animals Expressing Humanized CD3 ComplexFebruary 2024June 2025Allow1601YesNo
18410576ABSOLUTE PRECIPITATION OF EXOSOMES (APEX) ISOLATIONJanuary 2024September 2024Allow810NoNo
18541448GENERATION OF ALVEOLAR EPITHELIAL TYPE 1 (AT1) CELLSDecember 2023February 2025Allow1421YesNo
18562767AGENT FOR IMPROVING CANCER CACHEXIA AND METHOD FOR IMPROVING CANCER CACHEXIANovember 2023December 2024Abandon1310YesNo
18316688RECOMBINANT CONSTRUCTS AND TRANSGENIC FLUORESCENT ORNAMENTAL FISH THEREFROMMay 2023February 2025Allow2120NoNo
18187268TRANSDUCED T CELLS EXPRESSING HUMAN SSTR2 AND APPLICATION THEREOFMarch 2023February 2025Allow2320NoNo
18156205ASSAY FOR DRUG DISCOVERY BASED ON IN VITRO DIFFERENTIATED CELLSJanuary 2023March 2025Allow2610YesNo
18081476RETINAL PIGMENT EPITHELIUM CELL COMPOSITIONSDecember 2022January 2025Abandon2531YesNo
18064441AGENT FOR ACCELERATING GROWTH OF PLURIPOTENT STEM CELLSDecember 2022February 2025Allow2720YesNo
18055312STEM CELL DERIVED ISLET DIFFERENTIATIONNovember 2022November 2023Allow1221YesNo
17932915CRISPR-CAS10 SYSTEMS AND METHODS FOR PHAGE GENOME EDITINGSeptember 2022June 2025Allow3300NoNo
17943348HOMOGENIZATION METHOD OF INFECTING A MOSQUITO WITH WOLBACHIASeptember 2022April 2024Allow1921YesNo
17906145READY-TO-USE FLY NEONATE LARVAE WITH EXTENDED SHELF-LIFE AND METHODS OF PRODUCING SAMESeptember 2022June 2025Allow3331YesNo
17895405KIT AND METHOD FOR CONSTRUCTING LONG-ACTING DEPRESSION ANIMAL MODELAugust 2022February 2024Allow1811YesNo
17886067SYSTEMS AND METHODS FOR CELL CULTURINGAugust 2022April 2025Allow3211NoNo
17844757Method For Promoting Differentiation Of Pluripotent Stem Cells By Reducing Undifferentiated State ThereofJune 2022June 2024Allow2400NoNo
17830278ENGINEERED CELLS WITH IMPROVED PROTECTION FROM NATURAL KILLER CELL KILLINGJune 2022September 2023Abandon1611NoNo
17680843CHIMERIC GENE CONSTRUCTS FOR GENERATION OF FLUORESCENT TRANSGENIC ORNAMENTAL FISHFebruary 2022November 2024Abandon3310NoNo
17677208Toxicity Management for Anti-Tumor Activity of CARsFebruary 2022December 2024Abandon3310NoNo
17673453RNA ENGINEERED T CELLS FOR THE TREATMENT OF CANCERFebruary 2022May 2025Abandon3911NoNo
17671312IN VITRO PROLIFERATION MEDIUM, IN VITRO CULTURE KIT AND IN VITRO PROLIFERATION CULTURE METHOD OF UMBILICAL CORD BLOOD (UCB)-DERIVED NATURAL KILLER (NK) CELLSFebruary 2022May 2025Abandon3940NoNo
17666334METHOD OF GENERATING HEPATIC CELLSFebruary 2022June 2025Allow4021NoNo
17622364METHOD OF PREPARING MOUSE MODEL OF HERPESDecember 2021April 2025Allow4010NoNo
17557525TISSUE-DERIVED TISSUEGENIC IMPLANTS, AND METHODS OF FABRICATING AND USING SAMEDecember 2021May 2025Abandon4001NoNo
17552720METHODS FOR MODIFYING THE GROWTH RATE OF A CELLDecember 2021March 2025Abandon3920NoNo
17542997METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIESDecember 2021April 2024Abandon2840NoNo
17543020METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIESDecember 2021April 2024Abandon2840NoNo
17529686Amplifiable RNAs for Therapeutic Cell SystemsNovember 2021October 2024Abandon3501NoNo
17528936RED TRANSGENIC FLUORESCENT ORNAMENTAL FISHNovember 2021December 2024Allow3720YesNo
17528827TARGETED CANCER THERAPYNovember 2021February 2025Abandon3901NoNo
17511092METHODS AND COMPOSITIONS FOR MONITORING AND ENHANCING EARLY EMBRYO DEVELOPMENTOctober 2021April 2025Abandon4120NoNo
17506730NON-HUMAN ANIMALS EXPRESSING HUMANIZED C1Q COMPLEXOctober 2021September 2024Allow3521YesNo
17504502BLOOD TYPE O Rh- HYPO-IMMUNOGENIC CELLSOctober 2021April 2025Allow4111YesNo
17503143METHODS FOR GENERATING STEM CELL-DERIVED BETA CELLS AND METHODS OF USE THEREOFOctober 2021June 2024Allow3210NoNo
17498110GENE EDITING OF REPRODUCTIVE HORMONES TO REDUCE FERTILITY IN ICTALURUS PUNCTATUSOctober 2021January 2025Abandon4001NoNo
17493533MACS-BASED PURIFICATION OF STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUMOctober 2021October 2024Allow3711NoNo
17482991GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD137September 2021August 2024Abandon3410NoNo
17439184MODIFIED ADENOVIRUS AND MEDICINE COMPRISING SAMESeptember 2021April 2025Allow4311YesNo
17427449USE OF MOUSE MODEL IN EVALUATION OF INTELLIGENCE LEVELJuly 2021March 2025Allow4350YesNo
17444009PLATELET-RICH PLASMA COMPOSITIONS AND METHODS OF PREPARATIONJuly 2021September 2024Abandon3710NoNo
17385039HUMANIZED IL-6 AND IL-6 RECEPTORJuly 2021October 2024Allow3921YesNo
17368933NON-HUMAN ANIMAL EXHIBITING DIMINISHED UPPER AND LOWER MOTOR NEURON FUNCTION AND SENSORY PERCEPTIONJuly 2021August 2024Abandon3711NoNo
17358774GENE AND CELL THERAPY USING CELL FUSION TECHNOLOGYJune 2021April 2024Allow3310YesNo
17416044EMBRYONIC ERYTHROBLAST-CONTAINING CELL POPULATION AND METHOD FOR PRODUCING SAME, CELL CULTURE COMPOSITION, AND COMPOUND TEST METHODJune 2021November 2024Allow4111YesNo
17338795Purification and Purity Assessment of RNA Molecules Synthesized with Modified NucleosidesJune 2021March 2024Allow3310YesNo
17328980SCALABLE PRIMATE PLURIPOTENT STEM CELL AGGREGATE SUSPENSION CULTUREMay 2021October 2024Allow4120YesNo
17316494CANCER SCREENING AND THERAPEUTICSMay 2021January 2025Abandon4410NoNo
17241651USE OF RNA FOR REPROGRAMMING SOMATIC CELLSApril 2021April 2025Allow4751NoNo
17240373LYMPHANGIOGENESIS-PROMOTING AGENTSApril 2021September 2024Abandon4111NoNo
17206451METHOD OF GENERATING HEPATIC CELLSMarch 2021November 2021Allow711YesNo
17201977METHODS FOR MAKING AND USING MODIFIED OOCYTESMarch 2021March 2024Abandon3601NoNo
17173563Vip3A RESISTANT SPODOPTERA FRUGIPERDAFebruary 2021November 2024Abandon4531YesNo
17168603GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3eFebruary 2021February 2024Allow3611YesNo
17161376METHOD FOR IDENTIFYING, EXPANDING, AND REMOVING ADULT STEM CELLS AND CANCER STEM CELLSJanuary 2021January 2024Abandon3610NoNo
17131887HUMAN IPSC-BASED DERIVATION OF NK AND T-CELLS USING EARLY NOTCH INDUCTIONDecember 2020May 2023Allow2932YesNo
17254725OPTIMIZED CLN5 GENES AND EXPRESSION CASSETTES AND THEIR USEDecember 2020September 2024Allow4511YesNo
17118241Non-Human Animals Expressing Humanized CD3 ComplexDecember 2020November 2023Allow3511YesNo
17118045THERAPEUTIC AGENTSDecember 2020June 2023Allow3010NoNo
16972118PHARMACEUTICAL COMPOSITION COMPRISING MESENCHYMAL STEM CELLS AS EFFECTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASEDecember 2020March 2025Allow5150NoNo
17059059CAR NK CELLSNovember 2020February 2025Allow5121YesNo
17089409METHODS OF GENERATING ENUCLEATED ERYTHROID CELLS USING MYO-INOSITOLNovember 2020January 2024Abandon3801NoNo
17074970SYSTEMS AND METHODS FOR CELL CULTURINGOctober 2020April 2022Allow1840YesNo
17047937ENRICHMENT OF GENOME-EDITED CELLSOctober 2020February 2025Abandon5211NoNo
17064920MUTATIONS IN RHODOPSIN GENE IN ZEBRAFISH AND USES THEREOFOctober 2020April 2023Allow3100NoNo
17062362METHOD OF TREATING A MAMMAL WITH DIABETES ASSOCIATED KIDNEY DISEASE USING LOCAL ADMINISTRATION OF STEM CELLS WITH TRANSIENTLY REDUCED p53October 2020January 2025Abandon5121NoNo
16963074METHOD FOR PREPARING NON-HUMAN PRIMATE SOMATIC CELL CLONED ANIMALSeptember 2020May 2024Allow4621YesNo
17025057METHODS FOR SELECTIVE INHIBITION OF PLURIPOTENT STEM CELLSSeptember 2020December 2023Allow3910YesNo
16979640METHODS AND COMPOSITIONS FOR INDUCIBLE EXPRESSION OF NEUROTROPHIC FACTORSSeptember 2020November 2024Allow5031NoNo
17013143UNIVERSAL DONOR CELLSSeptember 2020May 2021Allow811YesNo
17012599METHOD FOR REDUCING IMMUNOGENICITY OF RNASeptember 2020August 2023Allow3511NoNo
17002252Interferon Production Using Short RNA DuplexesAugust 2020January 2024Allow4101NoNo
16969929ENGINEERED IMMUNE CELLS AS DIAGNOSTIC PROBES OF DISEASEAugust 2020April 2024Abandon4401NoNo
16991076METHOD FOR PRODUCING ADENOHYPOPHYSIS OR PRECURSOR TISSUE THEREOFAugust 2020June 2024Allow4621NoNo
16967917TREATMENT OF DEAFNESS BY GENE THERAPYAugust 2020August 2024Abandon4810NoNo
16966521TRANSCRIPTION REGULATORY ELEMENTS AND USES THEREOFJuly 2020January 2025Allow5311YesNo
16965568MODIFIED MONOCYTES/MACROPHAGES/DENDRITIC CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND USES IN DISEASES AND DISORDERS ASSOCIATED WITH PROTEIN AGGREGATESJuly 2020September 2024Abandon5021NoNo
16963880EXPRESSION VECTOR AND METHODJuly 2020January 2025Allow5421NoNo
16928774CELL CULTURE DEVICE AND CELL CULTURE METHODJuly 2020April 2025Abandon5721NoNo
16960441METHOD FOR PRODUCING CARDIOMYOCYTESJuly 2020July 2023Allow3621YesNo
16960285METHOD FOR GENETIC MANIPULATION OF SAP-FEEDING INSECTSJuly 2020November 2024Allow5221NoNo
16919456NOVEL AND EFFICIENT METHOD FOR REPROGRAMMING BLOOD TO INDUCED PLURIPOTENT STEM CELLSJuly 2020January 2024Allow4320YesNo
16917464METHOD FOR PRODUCING NA�VE PLURIPOTENT STEM CELLSJune 2020November 2023Abandon4001NoNo
16916836GENE AND CELL THERAPY USING CELL FUSION TECHNOLOGYJune 2020August 2023Allow3720NoNo
16915859RECOMBINANT CONSTRUCTS AND TRANSGENIC FLUORESCENT ORNAMENTAL FISH THEREFROMJune 2020February 2023Allow3110NoNo
16899540USE OF HAPLOTYPE OF SNP SITE ASSOCIATED WITH HYPOXIA TOLERANCE IN BREEDING OF MEGALOBRAMA AMBLYCEPHALAJune 2020March 2024Abandon4520YesNo
16892181FUNCTIONAL OLIGODENDROCYTES DERIVED FROM PLURIPOTENT STEM CELLS AND METHODS OF MAKING AND USING THE SAMEJune 2020July 2023Allow3710YesNo
16892000MIDBRAIN DOPAMINE (DA) NEURONS FOR ENGRAFTMENTJune 2020November 2023Allow4211YesNo
16882147TARGETED DELIVERY OF GLYCINE RECEPTORS TO EXCITABLE CELLSMay 2020March 2023Allow3410NoNo
16878362GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS FOR PRODUCING HEAVY CHAIN-ONLY ANTIBODIESMay 2020July 2023Allow3811NoNo
16877008THERAPEUTIC AGENTSMay 2020October 2020Allow510YesNo
16877035THERAPEUTIC AGENTSMay 2020August 2020Allow300YesNo
16877294DEVELOPMENT OF SUPERIOR CHIMERISM BY hiPSC ENGINEERING AND EMBRYO AGGREGATIONMay 2020August 2023Allow3811YesNo
16875486STEM CELL SUBPOPULATIONS WITH DIFFERENTIAL GSTT1 EXPRESSION OR GENOTYPEMay 2020July 2023Allow3821NoNo
16872226Non-Human Animals Expressing Humanized CD3 ComplexMay 2020July 2020Allow200NoNo
16870959BLOOD TYPE O Rh- HYPO-IMMUNOGENIC PLURIPOTENT CELLSMay 2020July 2021Allow1521YesNo
16857855METHOD FOR PRODUCING CHIMERIC ANIMALApril 2020July 2023Allow3921YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BERTOGLIO, VALARIE E.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
11
Examiner Affirmed
9
(81.8%)
Examiner Reversed
2
(18.2%)
Reversal Percentile
28.7%
Lower than average

What This Means

With a 18.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
117
Allowed After Appeal Filing
21
(17.9%)
Not Allowed After Appeal Filing
96
(82.1%)
Filing Benefit Percentile
19.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BERTOGLIO, VALARIE E - Prosecution Strategy Guide

Executive Summary

Examiner BERTOGLIO, VALARIE E works in Art Unit 1632 and has examined 1,062 patent applications in our dataset. With an allowance rate of 54.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner BERTOGLIO, VALARIE E's allowance rate of 54.9% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BERTOGLIO, VALARIE E receive 2.32 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BERTOGLIO, VALARIE E is 36 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +42.2% benefit to allowance rate for applications examined by BERTOGLIO, VALARIE E. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 19.5% of applications are subsequently allowed. This success rate is in the 12% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 42.8% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 25.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 26% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 83.1% of appeals filed. This is in the 73% percentile among all examiners. Of these withdrawals, 72.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 8.8% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.